These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
110 related articles for article (PubMed ID: 342393)
1. Protection against syngeneic tumor grafts induced by inoculation with normal allogeneic tissues. Bear RH; Roholt OA; Pressman D Immunol Commun; 1977; 6(6):547-58. PubMed ID: 342393 [TBL] [Abstract][Full Text] [Related]
2. Syngeneic tumor rejection induced by immunization with normal allogeneic tissues. Bear RH; Roholt OA; Pressman D Immunol Commun; 1977; 6(3):217-25. PubMed ID: 885580 [TBL] [Abstract][Full Text] [Related]
3. Alien histocompatibility determinants on the cell surface of sarcomas induced by methylcholanthrene. I. In vivo studies. Parmiani G; Invernizzi G Int J Cancer; 1975 Nov; 16(5):756-67. PubMed ID: 52628 [TBL] [Abstract][Full Text] [Related]
4. Cross-reactions between tumor cells and allogeneic normal tissues. Inhibition of a syngeneic lymphoma outgrowth in H-2 and non-H-2 alloimmune BALB/c mice. Parmiani G; Sensi ML; Carbone G; Colombo M; Pierotti M; Ballinari D; Hilgers J; Hilkens J Int J Cancer; 1982 Mar; 29(3):323-32. PubMed ID: 7068280 [TBL] [Abstract][Full Text] [Related]
5. Immune inhibition of allogeneic lymphoma cells in the peritoneal cavity of mice. Fioretti MC; Libarati M; Bonmassar E; Cudkowicz G Cancer Res; 1975 Jan; 35(1):30-6. PubMed ID: 1089042 [TBL] [Abstract][Full Text] [Related]
6. Common leukemia-associated antigen of DBA/2 mouse leukemia detected by tumor rejection and complement-dependent cytotoxicity assays. Kawashima K; Takeyama H; Takahashi T; Kato Y; Watanabe E; Suzuki H; Minam S; Isobe K; Yamada K; Ito Y Gan; 1979 Dec; 70(6):769-76. PubMed ID: 94022 [TBL] [Abstract][Full Text] [Related]
7. Differential antigenic expression of the DBA/2 lymphoma L1210 and its sublines: cross-reactivity with C3H mammary tumors as defined by syngeneic monoclonal antibodies. Rapp L; Fuji H Cancer Res; 1983 Jun; 43(6):2592-9. PubMed ID: 6342755 [TBL] [Abstract][Full Text] [Related]
8. Induction of tumor resistance in mice by L1210 leukemia cells persistently infected with HVJ (Sendai virus). Takeyama H; Kawashima K; Yamada K; Ito Y Gan; 1979 Aug; 70(4):493-501. PubMed ID: 229053 [TBL] [Abstract][Full Text] [Related]
9. Inhibition of syngeneic tumor growth in rats immunized with allogeneic skin grafts. Hosokawa M; Imamura M; Oikawa T; Nakayama M; Gotohda E; Sendo F; Kodama T; Kobayashi H Int J Cancer; 1976 Sep; 18(3):369-74. PubMed ID: 783054 [TBL] [Abstract][Full Text] [Related]
10. The nature of tolerance in adult recipient mice made tolerant of alloantigens with supralethal irradiation followed by syngeneic bone marrow cell transplantation plus injection of F1 spleen cells. Tomita Y; Himeno K; Mayumi H; Tokuda N; Nomoto K Transplantation; 1989 Jun; 47(6):1021-9. PubMed ID: 2660340 [TBL] [Abstract][Full Text] [Related]
11. Effects of ethylene glycol monomethyl (EGME) and monoethyl (EGEE) ethers on the immunocompetence of allogeneic and syngeneic mice bearing L1210 mouse leukemia. Houchens DP; Ovejera AA; Niemeier RW Environ Health Perspect; 1984 Aug; 57():113-8. PubMed ID: 6499794 [TBL] [Abstract][Full Text] [Related]
12. Studies on immunological tolerance induced in mice by kidney allografts. Inoue K; Niesen N; Albini B; Milgrom F Int Arch Allergy Appl Immunol; 1991; 96(4):358-61. PubMed ID: 1809693 [TBL] [Abstract][Full Text] [Related]
13. Effector cell stimulation-inhibition of in vitro lymphoma cell DNA synthesis and correlation with in vivo antitumor response. Gordon WC; Prager MD Cancer Res; 1977 Feb; 37(2):507-13. PubMed ID: 832275 [TBL] [Abstract][Full Text] [Related]
14. Early growth of experimental tumors and the onset of concomitant immunity. karakousis CP; Paolini NS; Sharma SD; Moore RH Eur J Cancer Clin Oncol; 1982 Feb; 18(2):211-7. PubMed ID: 6284514 [No Abstract] [Full Text] [Related]
15. Alloreactivity and tumor antigens: generation of syngeneic antilymphoma killer lymphocytes by alloimmunization of mice with normal cells. Sensi ML; Parenza M; Parmiani G J Natl Cancer Inst; 1983 Feb; 70(2):291-7. PubMed ID: 6571938 [TBL] [Abstract][Full Text] [Related]
16. Induction of resistance to L1210 leukemia in BALB/c X DBA/2Cr F1 mice, with L1210 cells treated with glutaraldehyde and concanavalin A. Kataoka T; Oh-hashi F; Tsukagoshi S; Sakurai Y Cancer Res; 1977 Apr; 37(4):964-8. PubMed ID: 403001 [TBL] [Abstract][Full Text] [Related]
17. The use of allogeneic stimulation and exogenous interleukin for syngeneic tumor rejection. Sherburne CG; Condie RM; Nnadi EC; Adlin M Transplant Proc; 1987 Feb; 19(1 Pt 1):628-31. PubMed ID: 3493564 [TBL] [Abstract][Full Text] [Related]
18. Genetic control of MuLV-gs expression in crosses between high and low leukemia incidence strains. Hilgers J; Galesloot J Int J Cancer; 1973 May; 11(3):780-93. PubMed ID: 4364724 [No Abstract] [Full Text] [Related]
19. Tumor-associated alien alloantigens of BALB/c tumors encoded by the MHC and by non-H-2 genes: a histogenetic study. Parmiani G; Ballinari D; Sensi ML J Immunol; 1980 Feb; 124(2):662-8. PubMed ID: 6153203 [No Abstract] [Full Text] [Related]
20. Therapeutic effectiveness of neuraminidase-treated tumor cells as an immunogen in man and experimental animals with leukemia. Bekesi JG; Roboz JP; Holland JF Ann N Y Acad Sci; 1976; 277(00):313-31. PubMed ID: 1069551 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]